<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278421</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000459685</org_study_id>
    <secondary_id>DSHNHL-2004-2</secondary_id>
    <secondary_id>EU-205110</secondary_id>
    <secondary_id>EUDRACT-2005-00521738</secondary_id>
    <secondary_id>DSHNHL-FLYER-6664</secondary_id>
    <nct_id>NCT00278421</nct_id>
  </id_info>
  <brief_title>Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter &lt;7,5cm) [FLYER 6-6-6-4 Study]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German High-Grade Non-Hodgkin's Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German High-Grade Non-Hodgkin's Lymphoma Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
      ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others
      interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy,
      such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to
      stop the growth of cancer cells, either by killing the cells or by stopping them from
      dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells.
      It is not yet known which schedule of rituximab and combination chemotherapy is more
      effective in treating non-Hodgkin's lymphoma.

      PURPOSE: This randomized phase III trial is studying two different schedules of rituximab and
      combination chemotherapy to compare how well they work in treating patients with aggressive
      B-cell non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the efficacy of 2 different schedules of immunochemotherapy comprising
           rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone in
           patients with previously untreated, low-risk, aggressive B-cell non-Hodgkin's lymphoma.

        -  Compare acute and chronic side effects in patients treated with these regimens.

        -  Compare time to treatment failure in patients treated with these regimens.

      Secondary

        -  Compare the time to progression in patients treated with these regimens.

        -  Compare the overall and disease-free/relapse-free survival of patients treated with
           these regimens.

        -  Compare the complete response rate in patients treated with these regimens.

        -  Compare the tumor control in patients treated with these regimens.

        -  Compare the safety of these regimens in these patients.

        -  Compare the pharmacoeconomics of these regimens.

        -  Compare patient adherence to these regimens.

      OUTLINE: This is an open-label, randomized, multicenter study. Patients are stratified
      according to participating center. Patients are randomized to 1 of 2 treatment arms.

      All patients are given the option of receiving a 1-week course of pretreatment therapy
      comprising vincristine IV once on day -6 and oral prednisone once daily on days -6 to 0.

        -  Arm I: Patients receive R-CHOP immunochemotherapy comprising rituximab IV,
           cyclophosphamide IV over 15 minutes, doxorubicin hydrochloride IV, and vincristine IV on
           day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 3
           courses in the absence of disease progression or unacceptable toxicity. Patients then
           undergo restaging of their disease. Patients with disease progression proceed to salvage
           therapy off study. All other patients receive 3 more courses of R-CHOP.

        -  Arm II: Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for 3
           courses in the absence of disease progression or unacceptable toxicity. Patients then
           undergo restaging of their disease. Patients with disease progression proceed to salvage
           therapy off study. All other patients receive 1 more course of R-CHOP followed by 2
           courses of rituximab alone.

      All patients undergo final restaging after 6 courses of rituximab. Patients with disease
      progression, stable disease, or partial response proceed to salvage therapy off study.

      After completion of study treatment, patients are followed periodically for 5 years and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 622 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure (TTF) measured from day 1 of course 1 of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) therapy up to 3 years on study with life-long follow-up</measure>
    <time_frame>through study completion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate duration until first relapse</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression rate during treatment</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor control measured from day 1 of course 1 of CHOP therapy (non-tumor related events are censored)</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival measured from day 1 of course 1 of CHOP therapy</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse events, serious adverse events) assessed at 3 months after treatment</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">592</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Interventional: 6 R-CHOP-21</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm I: Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 3 more courses of R-CHOP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional: 4 R-CHOP-21 + 2 x R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm II: Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 1 more course of R-CHOP followed by 2 courses of rituximab alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>Interventional: 6 R-CHOP-21</arm_group_label>
    <arm_group_label>Interventional: 4 R-CHOP-21 + 2 x R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Interventional: 6 R-CHOP-21</arm_group_label>
    <arm_group_label>Interventional: 4 R-CHOP-21 + 2 x R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Interventional: 6 R-CHOP-21</arm_group_label>
    <arm_group_label>Interventional: 4 R-CHOP-21 + 2 x R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <arm_group_label>Interventional: 6 R-CHOP-21</arm_group_label>
    <arm_group_label>Interventional: 4 R-CHOP-21 + 2 x R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Interventional: 6 R-CHOP-21</arm_group_label>
    <arm_group_label>Interventional: 4 R-CHOP-21 + 2 x R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed aggressive B-cell non-Hodgkin's lymphoma, including the
             following subtypes:

               -  Grade 3 follicular lymphoma

               -  Diffuse B-cell lymphoma, including diffuse large cell lymphoma with any of the
                  following variants:

                    -  Centroblastic

                    -  Immunoblastic

                    -  Plasmablastic

                    -  Anaplastic large cell

                    -  T-cell-rich B-cell lymphoma

               -  Primary effusion lymphoma

               -  Intravascular B-cell lymphoma

               -  Primary mediastinal B-cell lymphoma

               -  Burkitt's or Burkitt-like lymphoma

               -  Mantle cell lymphoma (blastoid)

               -  Aggressive marginal zone lymphoma (monocytoid)

          -  Previously untreated disease

          -  CD20-positive disease

          -  International Prognostic Index (IPI) score 0

          -  No bulky disease

               -  Largest single or conglomerate tumor &lt; 7.5 cm in diameter

          -  No mucosa-associated lymphoid tissue (MALT) lymphoma

          -  No CNS involvement of lymphoma (intracerebral, meningeal, or intraspinal)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Platelet count ≥ 100,000/mm^3

          -  WBC ≥ 2,500/mm^3

          -  Lactate dehydrogenase normal

          -  Not pregnant or lactating

          -  Fertile patients must use effective contraception during and for 1 year after study
             participation

          -  Negative pregnancy test

          -  No known hypersensitivity to the study medications

          -  No known HIV-positivity

          -  No active hepatitis infection

          -  No impaired left ventricular function

          -  No severe cardiac arrhythmias

          -  No other impaired organ function

          -  No other serious disorder

          -  No other malignancy within the past 5 years except carcinoma in situ or basal cell
             skin cancer

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy

          -  No prior immunosuppressive treatment with cytostatics

          -  No planned radiotherapy to extranodal involvement

          -  No concurrent participation in other treatment studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael G.M. Pfreundschuh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaetsklinikum des Saarlandes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haematologisch Onkologische Praxis</name>
      <address>
        <city>Aachen</city>
        <zip>52070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>DOH-86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>D-95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematologisch-Onkologische Schwerpunktpraxis - Weilheim</name>
      <address>
        <city>Berlin</city>
        <zip>13357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>D-12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franziskus Hospital</name>
      <address>
        <city>Bielefeld</city>
        <zip>D-33615</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta-Kranken-Anstalt gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>D-44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>G-38114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIAKO Ev. Diakonie Krankenhaus gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>D-28239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kuchwald Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <zip>D-09113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Fuer Haematologie Internistische Onkologie</name>
      <address>
        <city>Cologne</city>
        <zip>D-50677</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaetsklinik I at the University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>D-50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carl - Thiem - Klinkum Cottbus</name>
      <address>
        <city>Cottbus</city>
        <zip>D-03048</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Rheinhold Siegmund - Dr. Matthias Penke</name>
      <address>
        <city>Damme</city>
        <zip>D-49401</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>D-44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hans - Susemihl - Krankenhaus</name>
      <address>
        <city>Emden</city>
        <zip>26721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Eschweiler</city>
        <zip>DOH-52249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <zip>D-15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda</name>
      <address>
        <city>Fulda</city>
        <zip>D-36013</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Josef Hospital</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>D-45899</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet</name>
      <address>
        <city>Greifswald</city>
        <zip>D-17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Gummersbach GMBH</name>
      <address>
        <city>Gummersbach</city>
        <zip>D-51643</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH</name>
      <address>
        <city>Hagen</city>
        <zip>D-58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Sixtus Hospital</name>
      <address>
        <city>Haltern</city>
        <zip>D-45721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematologisch-Onkologische Praxis Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>D-22767</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien-Hospital Hamm - Klinik Knappenstrasse</name>
      <address>
        <city>Hamm</city>
        <zip>D-59071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Krankenhaus Hamm</name>
      <address>
        <city>Hamm</city>
        <zip>DOH-59063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruprecht - Karls - Universitaet Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bernward Krankenhaus</name>
      <address>
        <city>Hildesheim</city>
        <zip>D-31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>D-66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Bone Marrow Transplantation and Hematology and Oncology</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>D-55743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius - Kliniken</name>
      <address>
        <city>Karlsruhe</city>
        <zip>D-76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kempten Oberallgaeu</name>
      <address>
        <city>Kempten</city>
        <zip>D-87439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>D-24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas - Krakenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe - Lemgo</name>
      <address>
        <city>Lemgo</city>
        <zip>D-32657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz Hospital Limburg</name>
      <address>
        <city>Limburg</city>
        <zip>D-65549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein</name>
      <address>
        <city>Ludwigshafen am Rhein</city>
        <zip>D-67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Luedenscheid</name>
      <address>
        <city>Luedenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III Medizinische Klinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68305</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen und Marburg GmbH - Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>D-35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Ludmillenstift</name>
      <address>
        <city>Meppen</city>
        <zip>49716</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Maria Hilf GmbH</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>D-41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematologisch - Onkologische Gemeinschaftspraxis - Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik A - Universitaetsklinikum Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwaebisch Gmuend Stauferklinik</name>
      <address>
        <city>Mutlangen</city>
        <zip>D-73557</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerwpunktpraxis Dr. Ladda</name>
      <address>
        <city>Neumarkt</city>
        <zip>D-92318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lukaskrankenhaus Neuss</name>
      <address>
        <city>Neuss</city>
        <zip>D-41464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schlossbergkliniken Oberstaufen</name>
      <address>
        <city>Oberstaufen</city>
        <zip>D-87534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>D-26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pforzheim</city>
        <zip>75179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst Von Bergmann</name>
      <address>
        <city>Potsdam</city>
        <zip>D-14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosper-Hospital Recklinghausen</name>
      <address>
        <city>Recklinghausen</city>
        <zip>DOH-45659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostock</city>
        <zip>D-18257</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien - Krankenhaus Siegen GMBH</name>
      <address>
        <city>Siegen</city>
        <zip>D-57072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Mutterhaus der Borromaerinnen</name>
      <address>
        <city>Trier</city>
        <zip>D-54219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest German Cancer Center at Eberhard-Karls-University</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marienhospital - Vechta</name>
      <address>
        <city>Vechta</city>
        <zip>D-49377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Wendlingen</city>
        <zip>73240</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken Wuppertal University Hospital</name>
      <address>
        <city>Wuppertal</city>
        <zip>D-42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson Campus</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile - Piacenza</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cellulari ed Ematologia Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2006</study_first_submitted>
  <study_first_submitted_qc>January 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

